Organised by

université de TOURS
Inserm
LE STUDIO

Localisation of the congress
Hôtel Oceania L’Univers Tours
5 Bd Heurteloup 37000 Tours
France

Contact / website

brice.korkmaz@inserm.fr
isycatc2024.sciencesconf.org

Program
17 > 19 April 2024
Tours, France

4th INTERNATIONAL SYMPOSIUM ON CATHEPSIN C

ISyCatC IV
In honor of Prof. Christine Pham

With the support of

insmed
Chiesi
Boehringer Ingelheim

www.isycatc2024.sciencesconf.org
wednesday April 17th

16:00 Registration
17:45 Welcome cocktail reception
19:00 OPENING AND WELCOME SPEECH
   B. Korkmaz (France)
   • International cathepsin C consortium (Icat-CC)

19:05 C. Beaumont (Université de Tours, France)
   Vice-présidente en charge de la recherche

19:10 M. Si-Tahar (Inserm, France)
   Représentant régional

19:15 S. Gabillet (Le Studium, France)
   General Secretary, Loire Valley Institute for Advanced Studies

19:20 B. Korkmaz (France)
   • Cathepsin C inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease
   • Prof. Christine Pham’s biography

20:00 KEYNOTE LECTURE
   J. Chalmers (United Kingdom)
   • Clinical trials with cathepsin C inhibitors
   Discussion on pathophysiology/treatments

thursday April 18th

09:00 Session 1
PHYSIOLOGY AND PATHOPHYSIOLOGY
OF CATHEPSIN C TARGETS
   Chair: G. Lalmanach (France)

09:00 M. Novinec (Slovenia)
   • Exploring the impact of oligomeric state on cathepsin C activity

09:20 A. Aghdassi (Germany)
   • Intracellular vesicle transport and involvement of cathepsin C in acute pancreatitis

09:40 C. Pham (USA)
   • Cathepsin C: a historical perspective

10:05 Session 2
PHYSIOLOGY AND PATHOPHYSIOLOGY
OF CATHEPSIN C TARGETS
   Chair: A. Ö. Yildirim (Germany)

10:05 P. McDonald (Canada)
   • Cathepsin C and its substrates vs neutrophil functional responses
   Coffee break

11:00 T. Secher (France)
   • The proteolytic airway environment associated to pneumonia acts as a biological barrier for antibody treatment

11:20 N. Leborgne (Switzerland)
   • Neutrophil serine proteases degrade SARS-CoV-2 spike protein and reduce virus replication and inflammation in vivo

11:40 R. Stockley (UK)
   • Alpha-1 antitrypsin deficiency the path from antiproteases to clinical management

12:15 Lunch Buffet

14:30 Session 3
PHARMACOLOGICAL TARGETING
OF CATHEPSIN C
   Chair: M. Sieńczyk (Poland)

14:30 R. Domain (France)
   • Stability and activation of neutrophil elastase-related serine protease zymogens in myelomonocytic cells

15:10 I. Borek (Austria)
   • Inactivation of cathepsin C in pulmonary arterial hypertension

16:00 M. Rhimi (France)
   • Inactivation of cathepsin C in inflammatory bowel diseases

16:20 K.J. Chen (USA)
   • The role of a cathepsin C inhibitor in lupus nephritis

17:00 I. Couillin (France)
   • Consequences of cathepsin C inactivation in cigarette smoke or ozone-induced lung inflammation in mice

19:00 Gala Dinner

friday April 19th

09:00 Session 4
PHYSIOLOGY AND PATHOPHYSIOLOGY
OF CATHEPSIN C TARGETS
   Chair: G. Lalmanach (France)

09:00 M. Long (UK)
   • Clinical and phase I development of the novel oral cathepsin C inhibitor BI 1291583

09:40 G. Szabo (Germany)
   • Design of clinical trials evaluating cathepsin C inhibition in heart transplantation

10:00 Coffee break

10:20 C. Taggart (UK)
   • Pharmacological inhibition of cathepsin S and consequences for cathepsin C activation

11:40 D. Scherman (France)
   • Foundation for Rare Diseases (FFRD)

12:00 Lunch Buffet